Home
/
Foghorn Therapeutics Inc.
/
Financials
/
Quarterly
Foghorn Therapeutics Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Foghorn Therapeutics Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$8.15M
Nov 5, 2025
Q2
2025
Jun 30, 2025
$7.56M
Aug 5, 2025
Q1
2025
Mar 31, 2025
$5.95M
May 14, 2025
Q3
2025
Sep 30, 2024
$7.81M
Nov 5, 2025
Q2
2025
Jun 30, 2024
$6.89M
Aug 5, 2025
Q1
2025
Mar 31, 2024
$5.05M
May 14, 2025
Q3
2024
Sep 30, 2023
$17.48M
Nov 4, 2024
Q2
2024
Jun 30, 2023
$5.60M
Aug 8, 2024
Q1
2024
Mar 31, 2023
$5.31M
May 6, 2024
Q3
2023
Sep 30, 2022
$6.63M
Nov 2, 2023
Q2
2023
Jun 30, 2022
$4.49M
Aug 4, 2023
Q1
2023
Mar 31, 2022
$3.92M
May 8, 2023
Q3
2022
Sep 30, 2021
$41.0K
Nov 8, 2022
Q2
2022
Jun 30, 2021
$279.0K
Aug 9, 2022
Q1
2022
Mar 31, 2021
$286.0K
May 9, 2022
Q3
2021
Sep 30, 2020
$179.0K
Nov 9, 2021
Q2
2021
Jun 30, 2020
$0
Aug 10, 2021
Q1
2021
Mar 31, 2020
$0
May 11, 2021
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($15.85M)
Nov 5, 2025
Q2
2025
Jun 30, 2025
($17.94M)
Aug 5, 2025
Q3
2025
Jun 30, 2025
($17.94M)
Nov 5, 2025
Q3
2025
Mar 31, 2025
($18.83M)
Nov 5, 2025
Q1
2025
Mar 31, 2025
($18.83M)
May 14, 2025
Q2
2025
Mar 31, 2025
($18.83M)
Aug 5, 2025
Q3
2025
Sep 30, 2024
($19.12M)
Nov 5, 2025
Q2
2025
Jun 30, 2024
($22.98M)
Aug 5, 2025
Q3
2025
Jun 30, 2024
($22.98M)
Nov 5, 2025
Q3
2025
Mar 31, 2024
($25.02M)
Nov 5, 2025
Q2
2025
Mar 31, 2024
($25.02M)
Aug 5, 2025
Q1
2025
Mar 31, 2024
($25.02M)
May 14, 2025
Q3
2024
Sep 30, 2023
($14.35M)
Nov 4, 2024
Q2
2024
Jun 30, 2023
($29.49M)
Aug 8, 2024
Q3
2024
Jun 30, 2023
($29.49M)
Nov 4, 2024
Q1
2024
Mar 31, 2023
($30.49M)
May 6, 2024
Q3
2024
Mar 31, 2023
($30.49M)
Nov 4, 2024
Q2
2024
Mar 31, 2023
($30.49M)
Aug 8, 2024
Q3
2023
Sep 30, 2022
($25.77M)
Nov 2, 2023
Q3
2023
Jun 30, 2022
($27.31M)
Nov 2, 2023
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($18.50M)
Nov 5, 2025
Q2
2025
Jun 30, 2025
($21.10M)
Aug 5, 2025
Q1
2025
Mar 31, 2025
($22.91M)
May 14, 2025
Q3
2025
Sep 30, 2024
($23.85M)
Nov 5, 2025
Q2
2025
Jun 30, 2024
($26.63M)
Aug 5, 2025
Q1
2025
Mar 31, 2024
($28.19M)
May 14, 2025
Q3
2024
Sep 30, 2023
($17.08M)
Nov 4, 2024
Q2
2024
Jun 30, 2023
($32.05M)
Aug 8, 2024
Q1
2024
Mar 31, 2023
($33.32M)
May 6, 2024
Q3
2023
Sep 30, 2022
($28.26M)
Nov 2, 2023
Q2
2023
Jun 30, 2022
($29.19M)
Aug 4, 2023
Q1
2023
Mar 31, 2022
($27.80M)
May 8, 2023
Q3
2022
Sep 30, 2021
($26.26M)
Nov 8, 2022
Q2
2022
Jun 30, 2021
($23.26M)
Aug 9, 2022
Q1
2022
Mar 31, 2021
($23.13M)
May 9, 2022
Q3
2021
Sep 30, 2020
($18.49M)
Nov 9, 2021
Q2
2021
Jun 30, 2020
($15.54M)
Aug 10, 2021
Q1
2021
Mar 31, 2020
($13.72M)
May 11, 2021
Q3
2020
Sep 30, 2019
($13.10M)
Dec 4, 2020